Department of Obstetrics and Gynecology, Toho University Ohashi Medical Center, Tokyo, Japan.
Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan.
J Gynecol Oncol. 2023 Jul;34(4):e49. doi: 10.3802/jgo.2023.34.e49. Epub 2023 Mar 6.
To examine the effectiveness of progestin re-treatment for recurrent endometrial intraepithelial neoplasia (EIN), atypical endometrial hyperplasia (AH) and endometrial cancer (EC) following initial fertility-sparing treatment.
A comprehensive systematic review and meta-analysis were conducted by an Expert Panel of the Japan Society of Gynecologic Oncology Endometrial Cancer Committee. Multiple search engines, including PubMed/MEDLINE and the Cochrane Database, were searched in December 2021 using the keywords "Endometrial neoplasms," "Endometrial hyperplasia," "Endometrial intraepithelial neoplasia," "Fertility preservation," "Progestins," AND "Recurrence." Cases describing progestin re-treatment for recurrent EIN, AH and EC were compared with cases that underwent conventional hysterectomy. The primary outcomes were survival and disease recurrence, and the secondary outcome was pregnancy.
After screening 238 studies, 32 with results for recurrent treatment were identified. These studies included 365 patients (270 received progestin re-treatment and 95 underwent hysterectomy). Most progestin re-treatment involved medroxyprogesterone acetate or megestrol acetate (94.5%). Complete remission (CR) following progestin re-treatment was achieved in 219 (81.1%) cases, with 3-, 6- and 9-month cumulative CR rates of 22.8%, 51.7% and 82.6%, respectively. Progestin re-treatment was associated with higher risk of disease recurrence than conventional hysterectomy was (odds ratio [OR]=6.78; 95% confidence interval [CI]=1.99-23.10), and one patient (0.4%) died of disease. Fifty-one (14.0%) women became pregnant after recurrence, and progestin re-treatment demonstrated a possibility of pregnancy (OR=2.48; 95% CI=0.94-6.58).
This meta-analysis suggests that repeat progestin therapy is an effective option for women with recurrent EIN, AH and EC, who wish to retain their fertility.
探讨孕激素治疗初始保留生育功能治疗后复发的子宫内膜上皮内瘤变(EIN)、不典型子宫内膜增生(AH)和子宫内膜癌(EC)的有效性。
日本妇科肿瘤学会子宫内膜癌委员会专家小组进行了全面的系统评价和荟萃分析。2021 年 12 月,使用“子宫内膜肿瘤”、“子宫内膜增生”、“子宫内膜上皮内瘤变”、“生育力保留”、“孕激素”和“复发”等关键词,通过多个搜索引擎(包括 PubMed/MEDLINE 和 Cochrane 数据库)进行检索。将接受孕激素再治疗的复发性 EIN、AH 和 EC 病例与接受常规子宫切除术的病例进行比较。主要结局为生存和疾病复发,次要结局为妊娠。
经过筛选 238 项研究,确定了 32 项复发治疗的研究。这些研究共纳入 365 例患者(270 例接受孕激素再治疗,95 例接受子宫切除术)。孕激素再治疗多采用甲羟孕酮或甲地孕酮(94.5%)。219 例(81.1%)患者经孕激素再治疗后获得完全缓解(CR),3、6 和 9 个月的累积 CR 率分别为 22.8%、51.7%和 82.6%。与常规子宫切除术相比,孕激素再治疗后疾病复发的风险更高(比值比[OR]=6.78;95%置信区间[CI]=1.99-23.10),且有 1 例(0.4%)患者死于疾病。51 例(14.0%)患者复发后妊娠,孕激素再治疗显示出妊娠的可能性(OR=2.48;95% CI=0.94-6.58)。
本荟萃分析表明,对于希望保留生育能力的复发 EIN、AH 和 EC 患者,重复孕激素治疗是一种有效的选择。